Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Reports Increased Revenues, Flat Losses for Q2

NEW YORK, July 22 -Millennium Pharmaceuticals reported increased revenues for the second quarter, amid flat net losses and significant restructuring charges.


The company's revenues for the quarter totaled $121.7 million, compared to $91.9 million for the second quarter of 2002.


R&D expenses rose slightly to $130.6 million, from $122.4 million for the year-ago period.


The company's net losses for the quarter were $107.1 million, compared to $107.7 million for the same period of 2002.


The company in June announced a major restructuring, and its expenses included a $65.3 million restructuring charge related to facilities that Millennium is no longer going to use, the company said.


At the end of June, Millennium had $965.8 million in cash, cash equivalents and marketable securities.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.